




<rss xmlns:a10="http://www.w3.org/2005/Atom" version="2.0">
    <channel>
        <title>Anticoagulation Management</title>
        <link>http://www.acc.org/Feed?clinicalTopicID=677b3288-77e4-47f8-8697-3e2ce6a4dd87</link>
        <description>Clinical Topic Feed: Anticoagulation Management</description>
        <language>en</language>

        

                <item>
                    <title>TAVI PCI, ACASA-TAVI, TRIC-I-HF: New Answers in Structural Heart Care</title>
<link>/Latest-in-Cardiology/Articles/2026/08/29/08/48/sun-545am-combo-tavi-esc-2026</link>                    <description>Three late-breaking trials presented at ESC Congress 2026 offer new insights into the management of structural heart disease and heart failure (HF), spanning coronary revascularization during TAVI, transcatheter treatment of tricuspid regurgitation, and post-TAVI antithrombotic therapy. Together, the TAVI PCI, ACASA-TAVI and TRIC-I-HF studies provide important evidence to help refine treatment strategies and improve patient outcomes.</description>
                    <pubdate>1788091440000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Interventional Highlights From LIBREXIA ACS, PREMIUM, SWITCH SWEDEHEART, A-CLOSE, EPIDAURUS</title>
<link>/Latest-in-Cardiology/Articles/2026/08/24/12/30/sat-6am-combo-interventional-esc-2026</link>                    <description>Interventional science was the focus of a Hot Line Session at ESC Congress 2026, with studies shedding light on milvexian with antiplatelet therapy following an acute coronary event; aspirin omission at the time of primary PCI in STEMI; switching from ticagrelor to prasugrel following PCI in patients with acute coronary syndrome (ACS); clopidogrel vs. extended DAPT after high-risk PCI; and potent antiplatelet therapy in patients with atrial fibrillation (AFib) following myocardial infarction (MI).</description>
                    <pubdate>1788005340000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>SINGLE-AF: DOAC Therapy vs. No Anticoagulation in AFib Patients at Intermediate Risk For Stroke</title>
<link>/Latest-in-Cardiology/Articles/2026/08/24/12/30/fri-515am-single-af-esc-2026</link>                    <description>In patients with atrial fibrillation (AFib) at intermediate risk for stroke, DOAC therapy resulted in a lower risk of stroke, systemic embolism, major bleeding or death from cardiovascular causes at 24 months compared with no anticoagulation.</description>
                    <pubdate>1787912460000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>COMBINE-AF: Extracranial Bleeding Common With OAC in AFib Treatment</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/08/10/15/19/COMBINE-AF</link>                    <description>Clinically relevant extracranial bleeding affected approximately one in four patients receiving oral anticoagulation (OAC) for atrial fibrillation (AFib) over two years, potentially providing a more comprehensive measure of bleeding burden than major bleeding alone, according to a recent COMBINE-AF analysis published in Circulation.</description>
                    <pubdate>1786546740000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Eagle&#39;s Eye View: Lifestyle Intervention Benefits Health Status in ANOCA Patients</title>
<link>/Latest-in-Cardiology/Articles/2026/08/10/13/07/eagles-eye-view-12aug2026</link>                    <description>In this week&#226;€™s View, Dr. Eagle looks at the wide variation in antithrombotic regimens after valve-in-valve transcatheter aortic valve replacement (TAVR). Next, he examines PARTNER-3, a 7-year study on TAVR versus surgical aortic valve replacement (SAVR) outcomes in low-risk patients.</description>
                    <pubdate>1786537680000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Wide Variation in Antithrombotic Regimens After Valve-in-Valve TAVR | NCDR Study</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/08/03/10/06/Wide-Variation-in-Antithrombotic-Regimens</link>                    <description>There is wide variation in antithrombotic regimens after valve-in-valve (ViV) TAVR and no significant differences in outcomes, according to a study published July 27 in JACC: Cardiovascular Interventions.</description>
                    <pubdate>1785780360000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>ACC Featured Jobs For August 2026</title>
<link>/Latest-in-Cardiology/Articles/2022/01/01/01/01/ACC-Featured-Jobs</link>                    <description>Ready to explore a new professional opportunity? Browse the list below of featured jobs and take the next step in your career!</description>
                    <pubdate>1785581280000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>OPTIMA-AF: 1-Month vs. 12-Month Dual Antithrombotic Therapy Post PCI</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/07/28/17/19/OPTIMA-AF</link>                    <description>Only one month of dual antithrombotic therapy followed by direct oral anticoagulant (DOAC) monotherapy proved to be noninferior in terms of efficacy and superior in terms of bleeding outcomes to the standard 12-month dual antithrombotic therapy post PCI among patients with atrial fibrillation (AFib), according to results of the OPTIMA-AF trial published July 15 in The Lancet.</description>
                    <pubdate>1785260580000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Eagle&#226;€™s Eye View: Can Sugar-Sweetened Beverages and Fruit Juice Lead to Hypertension?</title>
<link>/Latest-in-Cardiology/Articles/2026/07/08/14/16/eagles-eye-view-08jul2026</link>                    <description>In this week&#226;€™s View, Dr. Eagle looks at withdrawing guideline-directed medical therapy (GDMT) for patients with atrial fibrillation (AF).</description>
                    <pubdate>1783520220000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Discontinuation of Anticoagulation Following Catheter Ablation of AF: Updates With OCEAN Trial</title>
<link>/Latest-in-Cardiology/Articles/2026/06/29/15/28/Discontinuation-of-Anticoagulation</link>                    <description>Current guidelines for management of atrial fibrillation (AF) recommend continuation of oral anticoagulation (OAC) following successful catheter ablation of AF for patients deemed at elevated thromboembolic risk.</description>
                    <pubdate>1782921180000</pubdate>
                    <category>Articles and Stories</category>
                </item>

    </channel>
</rss>